RHCOLLAGEN - THE IDEAL BUILDING BLOCK FOR REGENERATIVE MEDICINE

Yehiel Tal, CollPlant Ltd., Israel

- **Investment Rational**
  CollPlant is a regenerative medicine company focused on 3D Bioprinting of Tissues and Organs, Medical Aesthetics, Orthobiologics, and Advanced Wound Care markets. Our products are based on rhCollagen produced in genetically-engineered tobacco plants. CollPlant has 3 commercial products, and strategic collaboration with United Therapeutics for manufacturing of lung transplants. Our product pipeline is targeting a multi-billion market potential. Company management is comprised of industry veterans with track record of success.

- **Business Strategy**
  Key elements of our strategy include the following:
  ❖ Position our rhCollagen as the “gold standard” platform technology for collagen-based products in a broad range of markets.
  ❖ Expand sales infrastructure of our commercial products.
  ❖ Expand our pipeline through ongoing development of new products.
  ❖ Utilize collaborative partners and distributors to develop and commercialize products.

- **Core Technology**
  CollPlant’s Type I rhCollagen (recombinant human Collagen) is produced with our proprietary plant-based genetic engineering technology. The rhCollagen is identical to the collagen produced by the human body, has significant advantages compared to currently marketed tissue-derived collagens, including improved biological function, high homogeneity, and reduced risk of immune response. The physical properties of our rhCollagen make it an optimal building block for scaffolds for regenerative medicine including for 3D bioprinting of tissues and organs.

- **Product Profile/Pipeline**
  **3 commercial products:**
  - BioInk for 3D bioprinting of tissues and organs.
  - VergenixSTR for treatment of tendinopathy.
  - VergenixFG for the treatment of chronic and acute wounds.
  **Product pipeline:**
  - Dermal filler product line, addressing the need for more innovative aesthetic products to treat wrinkles
  - Prosthetic organoids such as ovary

  The annual market size for the above currently exceeded $8 billion

- **What’s Next?**
  Our rhCollagen represents a platform for the development of products addressing significant opportunities in regenerative medicine related markets.
  We continue to develop additional products based on our rhCollagen, both independently and with strategic collaborators, initially in 3D bioprinting of tissues and organs, dermal fillers for aesthetics, Orthobiologics and advanced wound care markets and subsequently in other high value markets.